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Introduction {#ams2486-sec-0006}
============

Extracorporeal membrane oxygenation (ECMO) is used for patients with acute severe cardiac or respiratory failure who are refractory to optimal conventional therapy.[1](#ams2486-bib-0001){ref-type="ref"} Recent studies reported on the increasing number and improving outcomes of ECMO cases, especially for patients on ECMO for respiratory support.[2](#ams2486-bib-0002){ref-type="ref"}, [3](#ams2486-bib-0003){ref-type="ref"} Significantly, most of the favorable outcomes of adult respiratory ECMO were reported by high‐volume ECMO centers.[4](#ams2486-bib-0004){ref-type="ref"}, [5](#ams2486-bib-0005){ref-type="ref"}, [6](#ams2486-bib-0006){ref-type="ref"}, [7](#ams2486-bib-0007){ref-type="ref"}

Because ECMO is a complex and high resource‐use procedure, consolidating ECMO treatment in high‐volume, dedicated centers have been proposed to improve outcomes and optimize health‐care resources.[8](#ams2486-bib-0008){ref-type="ref"} It has been also suggested that any ECMO indications would contribute to the accumulation of experience in respiratory ECMO, as ECMO for respiratory failure could be one component of the full spectrum of extracorporeal support.[8](#ams2486-bib-0008){ref-type="ref"}

By contrast, in Japan, insufficient centralization of respiratory ECMO treatment is clinically often said to adversely affect mortality and pursuing the centralization of respiratory ECMO cases remains an issue.[9](#ams2486-bib-0009){ref-type="ref"} However, few studies other than some involving small‐sized questionnaire surveys or registry data have attempted to describe institutional ECMO volume in Japan,[10](#ams2486-bib-0010){ref-type="ref"}, [11](#ams2486-bib-0011){ref-type="ref"} which implies that the efficacy of centralizing ECMO cases remains unclear.

Thus, the aim of this study was twofold: to investigate the epidemiology of ECMO in Japan by using a national‐level inpatient database and to examine the possible association between mortality in respiratory ECMO cases and the institutional case volume of ECMO for any indications.

Methods {#ams2486-sec-0007}
=======

Data source {#ams2486-sec-0008}
-----------

For our analysis, we used the national‐level Diagnosis Procedure Combination (DPC) administrative claims database. The DPC system involves a case‐mix classification for insurance reimbursements and is used in more than 1,700 acute‐care hospitals with approximately 490,000 beds. In 2018, DPC hospitals accounted for 83% of all acute‐care beds in Japan.[12](#ams2486-bib-0012){ref-type="ref"} The data were collected by the DPC Study Group, funded by the Japanese Ministry of Health, Labour and Welfare, and were obtained from approximately 80% of all DPC hospitals, with approximately 8 million inpatient episodes per year. The DPC data contain not only claims data for all clinical procedures and prescribed drugs during hospitalization, but also clinical summaries of the hospitalizations, such as patient demographics, diagnoses, comorbidities, and outcomes at discharge. Diseases are classified on the basis of the International Classification of Diseases, 10th Revision (ICD‐10) codes.

Patient selection {#ams2486-sec-0009}
-----------------

We identified patients aged ≥18 years who underwent ECMO between 1 July 2010 and 31 March 2018. The ECMO procedure codes in DPC contain codes for cardiopulmonary bypass used in the operating room for cardiac surgery, so we excluded patients who underwent ECMO only on the operation day. Based on previous studies using an administrative database, ECMO indications for ECMO‐treated patients were classified by the operation codes or highest resource‐use diagnoses as follows: post‐cardiotomy, cardiogenic shock (ICD‐10 codes I05--08, I20--28, I33--35, I40--42, I46, and I49--51), cardiopulmonary failure (I26--28), respiratory failure (J09--18 and J40--99), trauma/hypothermia/drowning (S%, T0%, T68, T751, and W65--74), sepsis (A40--41), pre‐ and post‐heart transplant status, and pre‐ and post‐lung transplant status.[3](#ams2486-bib-0003){ref-type="ref"}, [13](#ams2486-bib-0013){ref-type="ref"}, [14](#ams2486-bib-0014){ref-type="ref"} The classification process was undertaken by using a hierarchical system of diagnostic or procedure code criteria to create mutually exclusive groups.

Variables and outcomes {#ams2486-sec-0010}
----------------------

Institutional case volume, the main independent variable of interest, was defined as the mean annual number of patients receiving any ECMO at each institution during the study period. We calculated this mean annual number of cases considering the data available periods of each of the institutions. The institutions were categorized into tertiles based on the institutional case volume, with approximately equal numbers of patients in each group. We included patient age and sex and the institutional case volume group as baseline characteristics of the ECMO cases classified by ECMO indication. The primary outcome was all‐cause in‐hospital mortality. The secondary outcome was the fraction of patients who were transferred to other institutions while on ECMO.

For the patients with ECMO indications for respiratory failure, the following patient characteristics, stratified by institutional volume, were also evaluated based on several variables included in the Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score,[15](#ams2486-bib-0015){ref-type="ref"} the model for predicting survival for patients receiving ECMO for respiratory failure. These variables were age (18--49, 50--59, and ≥60 years), immunocompromised status, central nervous system dysfunction, acute associated non‐pulmonary infection, cardiac arrest, the etiologies of acute respiratory failure, and procedures carried out before ECMO, including bicarbonate infusion and neuromuscular blockade agents, and the duration of mechanical ventilation use prior to initiation of ECMO (0--2, 3--6, and ≥7 days). The etiologies of acute respiratory failure were extracted based on the RESP score as well, such as viral pneumonia (ICD‐10 codes J13--18), bacterial pneumonia (J09--12 and A%), asthma (J45--46), trauma and burn (S60--70 and T60--70), aspiration pneumonia (J69), other acute respiratory diagnoses (J90--94), or non‐respiratory and chronic respiratory diagnoses.[15](#ams2486-bib-0015){ref-type="ref"}

Statistical analyses {#ams2486-sec-0011}
--------------------

Continuous variables were calculated as means and standard errors; categorical variables were calculated as percentages (proportions). The Kruskal--Wallis test and Pearson's χ^2^‐test were applied as appropriate to assess differences between groups. For the respiratory failure group, a multivariable logistic regression analysis was carried out to investigate the association of in‐hospital mortality with various factors, including institutional case volume and several components of the RESP score,[15](#ams2486-bib-0015){ref-type="ref"} while also accounting for the correlation among the patients treated at the same institution using random effects models. As some values for the duration of mechanical ventilation use prior to initiation of ECMO were missing, we undertook multiple imputations to replace these missing values with a set of substituted plausible values by creating 20 filled‐in complete datasets using the chained equations technique that modifies the predictive mean matching method to impute missing data.[16](#ams2486-bib-0016){ref-type="ref"} We regarded the missing pattern as missing completely at random or missing at random, and assumed that any systematic differences between the missing and observed values could be explained by differences in the observed data.[17](#ams2486-bib-0017){ref-type="ref"} We carried out a complete case analysis as well. As a sensitivity analysis, we examined the volume‐outcome relationship by redefining the institutional case volume groups as the cut‐off points \<6, 6--14, 15--30, and \>30 based on previous studies on institutional volume of ECMO.[7](#ams2486-bib-0007){ref-type="ref"} All hypotheses were tested using a two‐sided test with a significance level of 0.05, and all statistical analyses were undertaken using the R statistical version 3.5.0 software.

Ethical considerations {#ams2486-sec-0012}
----------------------

This study was approved by the ethics committee of the Kyoto University Graduate School of Medicine (approval no. R0135; Kyoto, Japan). In accordance with the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects as stipulated by the Japanese national government, the requirement for informed consent was waived in the present study because of the patients' anonymity.

Results {#ams2486-sec-0013}
=======

Epidemiology of ECMO in Japan {#ams2486-sec-0014}
-----------------------------

We identified 25,384 patients from 725 hospitals who received ECMO during the study period. Table [1](#ams2486-tbl-0001){ref-type="table"} presents the size, baseline characteristics, and outcome variables of each indication group. During the study period, 1277 cases of respiratory ECMO were performed at 347 hospitals. Of all the ECMO indications, the fraction of respiratory failure was 5.0%, and that of cardiogenic shock was 70.5%. With regard to institutional case volume, ECMO for respiratory failure, trauma, sepsis, and heart or lung transplant tended to be undertaken in high‐volume institutions. The in‐hospital mortality rate was lowest in the respiratory failure group other than the transplant groups. In the respiratory failure group, the fraction of patients who were transferred to other institutions after initiating ECMO was not as high as in the other groups.

###### 

Patient demographics and outcomes of extracorporeal membrane oxygenation (ECMO cases in Japan classified by ECMO indications

                                              Respiratory failure   Cardiogenic shock   Post‐cardiotomy   Sepsis   Cardiopulmonary failure   Trauma/hypothermia/drowning   Lung transplant   Heart transplant   *P*‐value                                                                
  ------------------------------------------- --------------------- ------------------- ----------------- -------- ------------------------- ----------------------------- ----------------- ------------------ ----------- -------- ------- -------- ------- -------- ------- --------- ---------
  Number of patients                          1277                  17887               3184              1330     1167                      478                           49                12                                                                                          
  Number of institutions                      347                   709                 448               350      427                       208                           9                 4                                                                                           
  Male (%)                                    938                   (73.5)              13680             (76.5)   1971                      (61.9)                        984               (74.0)             448         (38.4)   303     (63.4)   25      (51.0)   9       (75.0)    \<0.001
  Age, years; mean (SD)                       61.35                 (15.2)              63.2              (14.8)   66.77                     (13.9)                        62.37             (14.8)             59.85       (16.1)   64.11   (20.4)   42.76   (12.0)   39.42   (8.1)     \<0.001
  Institutional case volume, cases/year (%)                                                                                                                                                                                                                                              
  Low (\<8)                                   400                   (31.3)              6550              (36.6)   1242                      (39.0)                        427               (32.1)             521         (44.6)   140     (29.3)   15      (30.6)   0       0.0       \<0.001
  Medium (8‐16)                               419                   (32.8)              5711              (31.9)   1021                      (32.1)                        418               (31.4)             365         (31.3)   147     (30.8)   3       (6.1)    0       0.0        
  High (≥17)                                  458                   (35.9)              5626              (31.5)   921                       (28.9)                        485               (36.5)             281         (24.1)   191     (40.0)   31      (63.3)   12      (100.0)    
  Transfer while on ECMO (%)                  7                     (0.5)               180               (1.0)    2                         (0.1)                         2                 (0.2)              18          (1.5)    4       (0.8)    0       0.0      0       0.0       \<0.001
  Death (%)                                   710                   (55.6)              12558             (70.2)   2065                      (64.9)                        1035              (77.8)             721         (61.8)   294     (61.5)   15      (30.6)   3       (25.0)    \<0.001

Comparison between the groups was evaluated with the Kruskal--Wallis test for numeric variables and Pearson's χ^2^‐test for categorical variables.
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Baseline variables of ECMO for respiratory failure {#ams2486-sec-0015}
--------------------------------------------------

Table [2](#ams2486-tbl-0002){ref-type="table"} shows the backgrounds and outcomes of the respiratory ECMO cases stratified by the institutional case volume groups. These respiratory cases were categorized into 400 low‐ (\<8 cases/year, *n* = 200 institutions), 419 medium‐ (8--16 cases/year, *n* = 96 institutions), and 498 high‐volume groups (≥17 cases/year, *n* = 51 institutions). No significant differences were found in the distribution of patient age, sex, respiratory ECMO indications, central nervous system dysfunction, acute associated non‐pulmonary infection, or use of neuromuscular blockade agents before ECMO among the three institutional volume groups. The most common cause of respiratory ECMO was bacterial infection. The high‐volume group tended to initiate ECMO soon after starting mechanical ventilation. Although the number of patients with cardiac arrest before ECMO was significantly high in the high‐volume group, the number of those with immunocompromised status and those with bicarbonate infusion before ECMO was significantly low in the high‐volume group. The low‐, medium‐, and high‐volume groups showed mortality rates of 62.5%, 54.7%, and 50.4%, respectively. The number of patients referred to other institutions while on ECMO was quite small and nearly equal among the three groups.

###### 

Baseline characteristics and outcomes of extracorporeal membrane oxygenation (ECMO) for respiratory failure categorized by annual institutional volume

  Annual institutional case volume groups (cases/year)           Low volume (\<8)   Medium volume (8--16)   High volume (≥17)   *P*‐value                  
  -------------------------------------------------------------- ------------------ ----------------------- ------------------- ----------- ----- -------- -------
  Number of patients                                             400                419                     458                                            
  Number of institutions                                         200                96                      51                                             
  Age group, years (%)                                                                                                                                     
  18--49                                                         86                 (21.5)                  96                  (22.9)      97    (21.2)   0.877
  50--59                                                         63                 (15.8)                  67                  (16.0)      82    (17.9)   
  ≥60                                                            251                (62.7)                  256                 (61.1)      279   (60.9)   
  Male (%)                                                       285                (71.3)                  320                 (76.4)      333   (72.7)   0.228
  Immunocompromised status (%)                                   75                 (18.8)                  66                  (15.8)      55    (12.0)   0.023
  Duration of mechanical ventilation use before ECMO, days (%)                                                                                             
  ≤2                                                             213                (53.2)                  268                 (64.0)      308   (67.2)   0.004
  3--6                                                           46                 (11.5)                  39                  (9.3)       41    (9.0)    
  ≥7                                                             65                 (16.2)                  51                  (12.2)      52    (11.4)   
  Null                                                           76                 (19.0)                  61                  (14.6)      57    (12.4)   
  Acute respiratory diagnosis group (%)                                                                                                                    
  Viral pneumonia                                                24                 (6.0)                   40                  (9.5)       44    (9.6)    0.58
  Bacterial pneumonia                                            170                (42.5)                  181                 (43.2)      200   (43.7)   
  Asthma                                                         19                 (4.8)                   14                  (3.3)       15    (3.3)    
  Trauma and burn                                                5                  (1.2)                   4                   (1.0)       5     (1.1)    
  Aspiration pneumonia                                           21                 (5.2)                   17                  (4.1)       27    (5.9)    
  Other acute respiratory diagnoses                              69                 (17.2)                  57                  (13.6)      65    (14.2)   
  Non‐respiratory and chronic respiratory diagnoses              92                 (23.0)                  106                 (25.3)      102   (22.3)   
  Central nervous system dysfunction before ECMO (%)             20                 (5.0)                   26                  (6.2)       21    (4.6)    0.542
  Acute associated non‐pulmonary infection (%)                   113                (28.2)                  130                 (31.0)      153   (33.4)   0.265
  Neuromuscular blockade agents before ECMO (%)                  229                (57.2)                  259                 (61.8)      279   (60.9)   0.369
  Bicarbonate infusion before ECMO (%)                           125                (31.2)                  146                 (34.8)      123   (26.9)   0.037
  Cardiac arrest before ECMO (%)                                 11                 (2.8)                   11                  (2.6)       29    (6.3)    0.006
  Transferred to other institutions while on ECMO (%)            2                  (0.5)                   3                   (0.7)       2     (0.4)    0.845
  Death (%)                                                      250                (62.5)                  229                 (54.7)      231   (50.4)   0.002

Comparison between the three groups was evaluated with Pearson's χ^2^‐test for categorical variables.
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Predictors of respiratory ECMO {#ams2486-sec-0016}
------------------------------

Table [3](#ams2486-tbl-0003){ref-type="table"} shows the results of a multivariable logistic regression model clustered by institutions with multiple imputation. After adjusting for the institutional case volume, baseline patient characteristics, respiratory ECMO etiologies, and medical procedures before ECMO, the high‐volume group showed a significantly lower mortality rate than the low‐volume group (odds ratio, 0.65; 95% confidence interval, 0.45--0.95; *P* = 0.024), whereas the mortality rate in the medium‐volume group tended to be lower, but not significantly so, than that in low‐volume group (odds ratio, 0.72; 95% confidence interval, 0.50--1.04; *P* = 0.082). The same tendency was observed in the complete case analysis and the sensitivity analysis involving redefining the cut‐off points of annual institutional case volume (Tables [4](#ams2486-tbl-0004){ref-type="table"} and [5](#ams2486-tbl-0005){ref-type="table"}).

###### 

Multivariable logistic regression with multiple imputation for analysis of annual institutional volume and other variables clustered within institutions

                                                             OR          (95% CI)       *P*‐value
  ---------------------------------------------------------- ----------- -------------- -----------
  Institutional case volume groups (cases/year)                                         
  Low (\<8)                                                  Reference                  
  Medium (8--16)                                             0.72        (0.50--1.04)   0.082
  High (≥17)                                                 0.65        (0.45--0.95)   0.024
  Age group, years                                                                      
  18--49                                                     Reference                  
  50--59                                                     1.59        (1.06--2.41)   0.027
  ≥60                                                        2.85        (2.05--3.96)   \<0.001
  Immunocompromised status                                   1.30        (0.91--1.88)   0.151
  Duration of mechanical ventilation use before ECMO, days                              
  ≤2                                                         Reference                  
  3--6                                                       1.75        (1.12--2.75)   0.016
  ≥7                                                         1.50        (0.97--2.31)   0.077
  Acute respiratory diagnosis group                                                     
  Viral pneumonia                                            Reference                  
  Bacterial pneumonia                                        1.10        (0.68--1.77)   0.694
  Asthma                                                     0.91        (0.41--2.01)   0.817
  Trauma and burn                                            0.93        (0.25--3.42)   0.910
  Aspiration pneumonitis                                     1.23        (0.60--2.54)   0.570
  Other acute respiratory diagnosis                          1.16        (0.66--2.03)   0.607
  Non‐respiratory and chronic respiratory diagnosis          0.76        (0.44--1.29)   0.308
  Central nervous system dysfunction before ECMO             1.90        (1.06--3.42)   0.032
  Acute associated non‐pulmonary infection                   1.16        (0.84--1.60)   0.377
  Neuromuscular blockade agents before ECMO                  0.53        (0.41--0.70)   \<0.001
  Bicarbonate infusion before ECMO                           2.70        (2.01--3.62)   \<0.001
  Cardiac arrest before ECMO                                 0.94        (0.49--1.80)   0.846

CI, confidence interval; ECMO, extracorporeal membrane oxygenation; OR, odds ratio.
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###### 

Adjusted odds ratios of annual institutional volume and other variables clustered within institutions in complete case analysis

                                                  OR          (95% CI)       *P*‐value
  ----------------------------------------------- ----------- -------------- -----------
  Institutional case volume groups (cases/year)                              
  Low (\<8)                                       Reference                  
  Medium (8--16)                                  0.77        (0.52--1.15)   0.201
  High (≥17)                                      0.58        (0.39--0.87)   0.008

ORs were adjusted for age (18--49, 50--59, and ≥60 years), immunocompromised status, duration of mechanical ventilation use prior to initiation of ECMO (0--2, 3--6, and ≥7 days), acute respiratory diagnosis group, central nervous system dysfunction before ECMO, acute associated non‐pulmonary infection, neuromuscular blockade agent before ECMO, bicarbonate infusion before ECMO, cardiac arrest before ECMO.

CI, confidence interval; OR, odds ratio.
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###### 

Adjusted odds ratios of annual institutional volume (cut‐off points: \<6, 6--14, 15--30, and \>30) and other variables clustered within institutions with multiple imputation

                                                 OR          (95% CI)       *P*‐value
  ---------------------------------------------- ----------- -------------- -----------
  Annual institutional case volume, cases/year                              
  \<6                                            Reference                  
  6--14                                          0.87        (0.59--1.28)   0.478
  15--30                                         0.6         (0.40--0.91)   0.016
  \>30                                           0.78        (0.41--1.46)   0.436

ORs were adjusted for age (18--49, 50--59, and ≥60 years), immunocompromised status, duration of mechanical ventilation use prior to initiation of ECMO (0--2, 3--6, and ≥7 days), acute respiratory diagnosis group, central nervous system dysfunction before ECMO, acute associated non‐pulmonary infection, neuromuscular blockade agent before ECMO, bicarbonate infusion before ECMO, cardiac arrest before ECMO.

CI, confidence interval; OR, odds ratio.
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Discussion {#ams2486-sec-0017}
==========

The present study characterized the current practices of ECMO cases in Japan and revealed a volume‐outcome relationship for adult respiratory ECMO by using nationwide administrative data. Contrary to previous studies using Extracorporeal Life Support (ELSO) registry data or an administrative database in the USA, the present study showed that the majority of the ECMO indications were for cardiac support; the proportion of ECMO indications for respiratory failure was relatively small. Thus, the selection of pumps, oxygenators, or cannulae might not be especially well‐suited for respiratory support in some institutions, a fact that could affect the prognosis of respiratory ECMO.

The present study showed a mortality rate for respiratory ECMO of 55.6%, which was less than the rate from the ELSO registry data but comparable to the rate shown in the US administrative data.[2](#ams2486-bib-0002){ref-type="ref"}, [13](#ams2486-bib-0013){ref-type="ref"} During the H1N1 pandemic, the survival rate of patients on respiratory ECMO in Japan was markedly low compared to that in other countries.[9](#ams2486-bib-0009){ref-type="ref"} Therefore, the Japanese Society of Respiratory Care Medicine started a training course for organized ECMO‐based respiratory programs in 2012 to introduce the routine practice of respiratory ECMO and to build a functional ECMO network system in Japan.[18](#ams2486-bib-0018){ref-type="ref"} Recent studies reported that outcomes for ECMO use in cases involving influenza‐associated acute respiratory failure in Japan markedly improved between 2009 and 2016.[19](#ams2486-bib-0019){ref-type="ref"} One of the contributing factors could be an improvement of the ECMO management skills for adult respiratory failure due to such ECMO training courses.

To the best of our knowledge, this is the first study based on administrative data to suggest that accumulating experience in the use of ECMO for any indications could positively affect the outcome of ECMO for respiratory failure. Generally, a volume‐outcome relationship has been found in some medical or surgical cases.[20](#ams2486-bib-0020){ref-type="ref"}, [21](#ams2486-bib-0021){ref-type="ref"} Previous studies using registry data between 1989 and 2013 showed a traditional volume‐outcome relationship in ECMO for respiratory failure; however, a study using US administrative data between 2002 and 2011 did not.[7](#ams2486-bib-0007){ref-type="ref"}, [13](#ams2486-bib-0013){ref-type="ref"} Of course, ECMO is merely a procedure for supportive care, so volume alone does not guarantee best practices or good outcomes; still, high‐volume centers could maintain robust expertise in the care and ventilatory management of patients with severe respiratory failure. Moreover, the criteria for determining ECMO implementation might differ depending on ECMO experience. Thus, consolidating ECMO cases by assigning them to expert referral centers could contribute to the improvement of outcomes.

Despite evidence suggesting the efficacy of consolidation, this study found that only a few patients under ECMO were transferred to higher‐volume facilities, which might indicate that consolidating ECMO cases has been promoted only on a very limited basis in Japan. Of course, transferring patients under severe conditions always involves risks. However, several studies have indicated that the transfer of patients on ECMO might not significantly increase mortality beyond the already‐high risk of ECMO itself when accompanied by high‐level technical expertise or equipment.[22](#ams2486-bib-0022){ref-type="ref"}, [23](#ams2486-bib-0023){ref-type="ref"} Recently, the establishment of a mobile ECMO system has been underway in Japan, a development that can be expected to advance the centralization of ECMO cases.[24](#ams2486-bib-0024){ref-type="ref"}

This study has several limitations. First, the DPC database does not include complete data on physiology, illness severity, or the details of medical procedures, such as ventilator settings or cannulation strategies. This lack of clinical information is a fundamental limitation of administrative data. Therefore, the severity adjustment in this study could be insufficient. However, we used the high impact factors included in the RESP score -- the prognostic factors of hospital discharge for respiratory ECMO -- as independent variables.[15](#ams2486-bib-0015){ref-type="ref"} Moreover, we determined the robustness of our model by imputing variables with missing values using the multiple imputation method or through sensitivity analysis. Second, our study samples were restricted to hospitals in the DPC Study Group, which could lead to a certain degree of selection bias. Nonetheless, this database included approximately 8 million inpatient records from \>80% of all acute‐care beds in Japan.[12](#ams2486-bib-0012){ref-type="ref"} Thus, the large sample size and diverse characteristics of the hospitals might reduce the potential selection bias. Given these factors, our sample could be reasonably considered representative of ECMO cases in Japan. Finally, the present study sampled only ECMO cases, which means that the results do not represent all patients with severe respiratory failure. As there may be no explicit standard for the introduction of ECMO, the criteria for determining ECMO implementation might differ between institutions. Further studies investigating severe respiratory failure both with and without ECMO are desirable for supporting our results.

Conclusions {#ams2486-sec-0018}
===========

The present study showed that many of the institutions in Japan undertook ECMO mainly for cardiac support. For cases involving ECMO for respiratory failure, a higher institutional case volume of ECMO treatment for any indications was significantly associated with lower in‐hospital mortality. Centralizing ECMO cases could improve the outcomes of patients needing respiratory ECMO.
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